Hepatocellular carcinoma a retrospective clinico-pathologic and immunohistochemical study of 15 cases

1. Bosch FX, Ribes J, Cléries R, Díaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2005;9:191-211.10.1016/j.cld.2004.12.00915831268Search in Google Scholar

2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.10.3322/caac.2010721296855Search in Google Scholar

3. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27:1485-91.10.1200/JCO.2008.20.7753266855519224838Search in Google Scholar

4. Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology. 2008;48:137-45.10.1002/hep.2231218537177Search in Google Scholar

5. Vălean S, Armean P, Resteman S, Nagy G, Mureşan A, Mircea PA. Cancer mortality in Romania, 1955-2004. Digestive sites: esophagus, stomach, colon and rectum, pancreas, liver, gallbladder and biliary tree. J. Gastrointestin Liver Dis. 2008;17(1):9-14.Search in Google Scholar

6. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013;58(3):593-608.10.1016/j.jhep.2012.12.00523419824Search in Google Scholar

7. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008;48 Suppl 1: S20-S37.10.1016/j.jhep.2008.01.02218304676Search in Google Scholar

8. Behne T, Copur MS. Biomarkers for hepatocellular carcinoma. Int J Hepatol. 2012:859076.10.1155/2012/859076335795122655201Search in Google Scholar

9. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the Digestive System 4th edn. IARC Press, Lyon, 2010:322-6.Search in Google Scholar

10. Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987;8:138-40.Search in Google Scholar

11. Guo RP, Zhong C, Shi M, Zhang CQ, Wei W, Zhang YQ, et al. Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2006;132(9):547-55.10.1007/s00432-006-0097-516763805Search in Google Scholar

12. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557-76.10.1053/j.gastro.2007.04.06117570226Search in Google Scholar

13. Mittal S, El-Serag HB. Epidemiology of Hepatocellular Carcinoma: Consider the Population. J Clin Gastroenterol. 2013. (Epub ahead of print)10.1097/MCG.0b013e3182872f29368311923632345Search in Google Scholar

14. Yu MW, Chang HC, Chang SC, Liaw YF, Lin SM, Liu CJ, et al. Role of reproductive factors in hepatocellular carcinoma: Impact on hepatitis B- and C-related risk. Hepatology. 2003;38:1393-400.Search in Google Scholar

15. Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol. 1995;8:2094-103.10.1200/JCO.1995.13.8.20947636553Search in Google Scholar

16. Burt AD, Portmann BC, Ferrell LD. MacSween’s Pathology of the Liver. 5th ed. 2007: 771-87.Search in Google Scholar

17. Lau SK, Prakash S, Geller SA, Alsabeh R. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma.Hum Pathol. 2002;33:1175-81.10.1053/hupa.2002.13010412514785Search in Google Scholar

18. Johnson DE, Herndier BG, Medeiros LJ, Warnke RA, Rouse RV. The diagnostic utility of the keratin profiles of hepatocellular carcinoma and cholangiocarcinoma. Am J Surg Pathol. 1988;12(3):187-97.10.1097/00000478-198803000-000042449824Search in Google Scholar

19. Kakar S, Gown AM, Goodman ZD, Ferrell LD. Best practices in diagnostic immunohistochemistry: hepatocellular carcinoma versus metastatic neoplasms. Arch Pathol Lab Med. 2007;131(11):1648-54.10.5858/2007-131-1648-BPIDIH17979482Search in Google Scholar

20. Heukamp LC , Fischer HP, Schirmacher P, Chen X, Breuhahn K, Nicolay C, et al. Podocalyxin-like protein 1 expression in primary hepatic tumours and tumour-like lesions. Histopathology. 2006;49(3):242-7.10.1111/j.1365-2559.2006.02489.x16918970Search in Google Scholar

21. Saad RS, Luckasevic TM, Noga CM, Johnson DR, Silverman JF, Liu YL. Diagnostic value of HepPar1, pCEA, CD10, and CD34 expression in separating hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration cytology. Diagn Cytopathol. 2004;30(1):1-6.10.1002/dc.1034514696137Search in Google Scholar

22. Balaton AJ, Nehama-Sibony M, Gotheil C, Callard P, Baviera EE. Distinction between hepatocellular carcinoma, cholangiocarcinoma, and metastatic carcinoma based on immunohistochemical staining for carcinoembryonic antigen and for cytokeratin 19 on paraffin sections. J Pathol. 1988;156(4):305-10.10.1002/path.17115604052465399Search in Google Scholar

23. Bonetti F, Chilosi M, Pisa R, Novelli P, Zamboni G, Menestrina F. Epithelial membrane antigen expression in cholangiocarcinoma. An useful immunohistochemical tool for differential diagnosis with hepatocarcinoma. Virchows Arch A Pathol Anat Histopathol. 1983;401:307-13.10.1007/BF007348476314640Search in Google Scholar

24. Chu PG, Ishizawa S, Wu E, Weiss LM. Hepatocyte antigen as a marker of hepatocellular carcinoma: an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein. Am J Surg Pathol. 2002;26(8):978-88.10.1097/00000478-200208000-0000212170084Search in Google Scholar

25. Imoto M, Nishimura D, Fukuda Y, Sugiyama K, Kumada T, Nakano S. Immunohistochemical detection of afetoprotein, carcinoembryonic antigen, and ferritin in formalin- paraffin sections from hepatocellular carcinoma. Am J Gastroenterol. 1985;80(11):902-6.Search in Google Scholar

26. Wee A. Diagnostic utility of immunohistochemistry in hepatocellular carcinoma, its variants and their mimics. Appl Immunohistochem Mol Morphol. 2006;14(3):266-72.10.1097/00129039-200609000-0000316932016Search in Google Scholar

27. El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology. 2001;33(1):62-5.10.1053/jhep.2001.21041Search in Google Scholar

28. Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin. 2012;62:118-28.10.3322/caac.20141Search in Google Scholar

29. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 2008;48:1312-27.10.1002/hep.22506Search in Google Scholar

30. Qin LX, Tang ZY. Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature J Cancer Res Clin Oncol. 2004;130(9):497-513.Search in Google Scholar

31. Hayashi H, Sugio K, Matsumata T, Adachi E, Takenaka K, Sugimachi K. The clinical signiWcance of p53 gene mutation in hepatocellular carcinoma from Japan. Hepatology. 1995;22(6):1702-7.Search in Google Scholar

32. Naka T, Toyota N, Kaneko T, Kaibara N. Protein expression of p53, p21WAF1, and Rb as prognostic indicators in patients with surgically treated hepatocellular carcinoma. Anticancer Res. 1998;18(1B):555-64.Search in Google Scholar

33. Qin LF, Ng IO. Expression of p27(KIP1) and p21(WAF1/CIP1) in primary hepatocellular carcinoma: clinicopathologic correlation and survival analysis. Hum Pathol. 2001;32(8):778-84. 10.1053/hupa.2001.27105Search in Google Scholar

34. Schöniger-Hekele M, Hänel S, Wrba F, Müller C. Hepatocellular carcinoma--survival and clinical characteristics in relation to various histologic molecular markers in Western patients. Liv Liver Int. 2005;25(1):62-9.10.1111/j.1478-3231.2004.0997.xSearch in Google Scholar

35. Sung CO, Yoo BC, Koh KC, Cho JW, Park CK. Prognostic significance of p53 overexpression after hepatic resection of hepatocellular carcinoma. Korean J Gastroenterol. 2005;45(6):425-30.Search in Google Scholar

36. Terris B, Laurent-Puig P, Belghitti J, Degott C, Hénin D, Fléjou JF. Prognostic influence of clinicopathologic features, DNAploidy, CD44H and p53 expression in a large series of resected hepatocellular carcinoma in France. Int J Cancer. 1997;74(6):614-9.10.1002/(SICI)1097-0215(19971219)74:6<614::AID-IJC10>3.0.CO;2-5Search in Google Scholar

37. Tseng PL, Tai MH, Huang CC, Wang CC, Lin JW, Hung CH, et al. Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients. J Surg Oncol. 2008 Oct 1;98(5):349-57.10.1002/jso.21109Search in Google Scholar

38. Kao WY, Su CW, Chau GY, Lui WY, Wu CW, Wu JC. A comparison of prognosis between patients with hepatitis B and C virus- related hepatocellular carcinoma undergoing resection surgery. World J Surg. 2011;35(4):858-67.10.1007/s00268-010-0928-zSearch in Google Scholar

39. Zhou J, Yan T, Bi X, Zhao H, Huang Z, Zhang Y, et al. Evaluation of seven different staging systems for alphafetoprotein expression in hepatocellular carcinoma after hepatectomy. Tumour Biol. 2013;34(2):1061-70.10.1007/s13277-013-0646-xSearch in Google Scholar

40. Changchien CS, Chen CL, Yen YH, Wang JH, Hu TH, Lee CM, et al. Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: prognostic features, treatment outcome, and survival. J Gastroenterol. 2008;43(2):159-70.10.1007/s00535-007-2134-9Search in Google Scholar

41. Japan LCSGi. Survey and follow-up study of primary liver cancer in Japan - report 11. Kanzo. 1995;36:208-18.10.2957/kanzo.36.208Search in Google Scholar

42. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology. 1998;28(3):751-5.10.1002/hep.5102803229731568Search in Google Scholar

43. Hu KQ, Kyulo NL, Lim N, Elhazin B, Hillebrand DJ, Bock T. Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. Am J Gastroenterol. 2004;99(5):860-5.10.1111/j.1572-0241.2004.04152.x15128351Search in Google Scholar

44. Yen YH, Changchien CS, Wang JH, Kee KM, Hung CH, Hu TH, et al. A modified TNM-based Japan Integrated Score combined with AFP level may serve as a better staging system for early-stage predominant hepatocellular carcinoma patients. Dig Liver Dis. 2009;41(6):431-41.10.1016/j.dld.2008.11.00819185555Search in Google Scholar

45. Ueland J, Yuan A, Marlier A, Gallagher AR, Karihaloo A. A novel role for the chemokine receptor cxcr4 in kidney morphogenesis: an in vitro study. Dev Dyn. 2009;238(5):1083-91.10.1002/dvdy.2194319384956Search in Google Scholar

46. Xiang ZL, Zeng ZC, Tang ZY, Fan J, Zhuang PY, Liang Y, et al. Chemokine receptor CXCR4 expression in hepatocellular carcinoma patients increases the risk of bone metastases and poor survival. BMC Cancer. 2009;9:176.10.1186/1471-2407-9-176270422019508713Search in Google Scholar

47. Li N, Guo W, Shi J, Xue J, Hu H, Xie D, et al. Expression of the chemokine receptor CXCR4 in human hepatocellular carcinoma and its role in portal vein tumor thrombus. J Exp Clin Cancer Res. 2010;29:156. 10.1186/1756-9966-29-156300232821110890Search in Google Scholar